(Reuters) -Drugmaker Eli Lilly is in advanced talks to acquire gene-editing startup Verve Therapeutics for up to $1.3 billion ...

HHS Secretary Robert F. Kennedy Jr. places anti-vaxxers in control of U.S. vaccine policy, slandering an actual expert along ...

The US Supreme Court on Monday declined to review a federal appeals court decision that Merck Sharpe & Dohme Corp. couldn’t ...

Artificial intelligence (AI) is no longer a distant innovation — it's now a core part of the pharmaceutical and life sciences ...

That challenge, of finding or building good, useable data sets, is also one of the biggest differentiators in an increasingly ...

Merck ( MRK) is a global biopharmaceutical giant with a diversified portfolio that spans across oncology, vaccines, ...

A Roots Analysis study showed the market for ADC manufacturing is $1.79 billion today, but is expected to grow to $7 billion ...

AQR Capital's Q1'25 portfolio hits $97.07B, with top picks in AAPL, NVDA, & AMZN. Active portfolio adjustments show a ...

ANGLE presents new data at EACR 2025 DEMONSTRATING DNA DUAL ANALYSIS FOR COMPREHENSIVE LIQUID BIOPSY PROFILING Poster highlights ANGLE's combined CTC-DNA and ctDNA analysis revealing tumour ...

During a live event, Hari Deshpande, MD, and participants discussed the DeFi trial and the management of nirogacestat in ...

Amid a spate of high-profile investments in U.S. pharmaceutical production, two contract manufacturers are getting in on the ...